MEMORANDUM

To: To Whom It May Concern

From: Richard S. Larson, MD, PhD
Executive Vice Chancellor
Vice Chancellor for Research

DATE: February 3, 2015

RE: UNM HSC Federalwide Assurance (FWA) for the Protection of Human Subjects

The Federal Wide Assurance number (FWA) for the University of New Mexico Health Sciences Center (UNM HSC) is FSW00003255. This FWA is current until February 3, 2020.

This Assurance applies whenever this Institution becomes engaged in human subjects research conducted or supported by any U.S. federal department or agency that has adopted the U.S. Federal Policy for the Protection of Human Subjects (also known as the Common Rule), unless the research is otherwise exempt from the requirements of the Common Rule or the department or agency conducting or supporting the research determines that the research shall be conducted under a separate assurance.

Under this agreement, the University of New Mexico Health Sciences Center (UNM HSC) assures that all of its activities related to human subjects research, regardless of the source of support, will be guided by The Belmont Report, a statement of principles governing the institution in the discharge of its responsibilities for protecting the rights and welfare of human subjects of research conducted at or sponsored by the institution. Additionally, the institution assures that whenever it engages in research to which this Assurance applies, it will comply with the Terms of the Federalwide Assurance (contained in a separate document on the Office for Human Research Protections (OHRP) website at http://hsc.unm.edu/som/research/hrrc/).

The following designated Institutional Review Boards (IRB) associated with this FWA are registered with the Department of Health and Human Services (DHHS).
IRB00000591 UNMHSC/School of Medicine IRB Committee 1
IRB00000592 UNMHSC/School of Medicine IRB Committee 2
IRB00001775 UNMHSC/School of Medicine IRB Committee 3

FDA requirement for IRB Registration
This registration fulfills the requirement of the Food and Drug Administration (FDA) under 21CFR56.106 that requires each IRB in the United States that reviews FDA-regulated studies to register under the DHHS system.